Monoclonal antibody A717

Drug Profile

Monoclonal antibody A717

Alternative Names: A 717; HuA717; HuA717 scFv

Latest Information Update: 08 May 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exocell
  • Developer Glycadia
  • Class Monoclonal antibodies
  • Mechanism of Action Glycosylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diabetic complications

Most Recent Events

  • 08 May 2003 No development reported - Preclinical for Diabetic complications in USA (unspecified route)
  • 22 Jul 1996 Exocell has a US patent to develop monoclonal antibody A717 for kidney disease and other complications of diabetes
  • 22 Jul 1996 Preclinical development for Diabetic complications in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top